NEOVACS : HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT  

Paris, January 14, 2015 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.

The liquidity account had the following holdings as of December 31, 2014:
   

•  76,340 shares
• €110,086.43

For the prior (June 30, 2014), the corresponding figures were:
    

• 15,631 shares
• €213,136.66

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr:
http://www.neovacs.fr

Contacts
                                                              
Néovacs                                                             
Nathalie Trépo                                                   
[phone]   
[e-mail]:
mailto:[e-mail] 

Publicis
Stéphanie Tabouis
Aubane de Gelis
[phone]
[e-mail]      

Neovacs:
http://hugin.info/160718/R/1887048/667442.pdf

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEOVACS via Globenewswire

HUG#1887048